Anthera Pharmaceuticals Company Profile (NASDAQ:ANTH)

About Anthera Pharmaceuticals

Anthera Pharmaceuticals logoAnthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ANTH
  • CUSIP:
Key Metrics:
  • Previous Close: $2.95
  • 50 Day Moving Average: $3.19
  • 200 Day Moving Average: $3.42
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.22
  • P/E Growth: 0.00
  • Market Cap: $123.04M
  • Outstanding Shares: 41,427,000
  • Beta: 1.95
Additional Links:
Companies Related to Anthera Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Anthera Pharmaceuticals (NASDAQ:ANTH) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $10.80 (263.64% upside)

Analysts' Ratings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Show:
DateFirmActionRatingPrice TargetDetails
8/10/2016Jefferies GroupReiterated RatingBuyView Rating Details
7/8/2016HC WainwrightInitiated CoverageBuy$10.00View Rating Details
6/20/2016FBR & CoReiterated RatingHoldView Rating Details
3/11/2016Piper Jaffray Cos.Lower Price TargetOverweight$14.00 -> $10.00View Rating Details
2/19/2016Citigroup Inc.Lower Price Target$15.00 -> $11.00View Rating Details
9/8/2015SunTrust Banks Inc.Initiated CoverageBuy$14.00View Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016        
8/9/2016Q2($0.31)($0.35)ViewN/AView Earnings Details
5/9/2016Q1($0.28)($0.29)ViewN/AView Earnings Details
3/10/2016Q4($0.27)($0.18)$1.92 millionViewN/AView Earnings Details
11/6/2015Q315($0.25)($0.29)ViewN/AView Earnings Details
8/10/2015Q2($0.28)($0.25)ViewN/AView Earnings Details
5/11/2015Q115($0.31)($0.28)ViewN/AView Earnings Details
3/16/2015($0.33)($0.32)ViewN/AView Earnings Details
11/14/2014($0.39)($0.31)ViewN/AView Earnings Details
7/28/2014($0.49)($0.34)ViewN/AView Earnings Details
5/13/2014Q114($0.46)($0.39)ViewN/AView Earnings Details
3/12/2014($0.47)($0.48)ViewN/AView Earnings Details
3/26/2013Q412($0.15)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)
Current Year EPS Consensus Estimate: $-1.33 EPS
Next Year EPS Consensus Estimate: $-1.34 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.30)($0.30)($0.30)
Q2 20162($0.30)($0.29)($0.30)
Q3 20162($0.35)($0.33)($0.34)
Q4 20162($0.32)($0.31)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anthera Pharmaceuticals (NASDAQ:ANTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.00View SEC Filing  
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.00View SEC Filing  
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.75View SEC Filing  
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateHeadline
News IconOTC Investors Keen on Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Duncan Research (NASDAQ:ANTH)
www.duncanindependent.com - August 27 at 8:19 AM
investornewswire.com logoWill Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Hit $14 Price Target? - Investor Newswire (NASDAQ:ANTH)
www.investornewswire.com - August 20 at 3:33 PM
News IconAnthera Pharmaceuticals, Inc.'s (ANTH): Running Mover to Focus - Hot Stocks Point (NASDAQ:ANTH)
www.hotstockspoint.com - August 18 at 3:38 PM
finance.yahoo.com logoANTHERA PHARMACEUTICALS INC Financials (NASDAQ:ANTH)
finance.yahoo.com - August 18 at 3:38 PM
marketwatch.com logoAnthera Pharma stock rises 7% on safety review board's go-ahead for late-stage drug trial - MarketWatch (NASDAQ:ANTH)
www.marketwatch.com - August 17 at 8:59 PM
News IconStock Gapping Up Pre-Market: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Post News (NASDAQ:ANTH)
www.kentuckypostnews.com - August 17 at 11:43 AM
News IconStock's Traders Recap- Anthera Pharmaceuticals, Inc.'s (ANTH) - Hot Stocks Point (NASDAQ:ANTH)
www.hotstockspoint.com - August 17 at 11:43 AM
finance.yahoo.com logoAnthera Pharmaceuticals (ANTH) Jumps: Stock Rises 7.9% (NASDAQ:ANTH)
finance.yahoo.com - August 17 at 11:43 AM
4-traders.com logoANTHERA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) (NASDAQ:ANTH)
www.4-traders.com - August 16 at 8:47 PM
reuters.com logoBRIEF-Anthera Pharmaceuticals names William Shanahan Jr. as chief medical officer (NASDAQ:ANTH)
www.reuters.com - August 16 at 8:47 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E (NASDAQ:ANTH)
biz.yahoo.com - August 16 at 8:47 PM
publicnow.com logoAnthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer (NASDAQ:ANTH)
www.publicnow.com - August 16 at 8:47 PM
News IconStock Moving Up in Session: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Post News (NASDAQ:ANTH)
www.kentuckypostnews.com - August 16 at 3:32 PM
reuters.com logoBRIEF-Anthera announces positive DSMB review in phase 3 solution study of Sollpura (NASDAQ:ANTH)
www.reuters.com - August 16 at 12:08 PM
finance.yahoo.com logoAnthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura™ (NASDAQ:ANTH)
finance.yahoo.com - August 16 at 12:08 PM
marketwatch.com logoAnthera Pharma stock rises 7% on safety review board's go-ahead for late-stage drug trial (NASDAQ:ANTH)
www.marketwatch.com - August 16 at 12:08 PM
247wallst.com logoTuesday’s Top Health Care Movers (NASDAQ:ANTH)
247wallst.com - August 16 at 12:08 PM
reuters.com logoBRIEF-Anthera Pharmaceuticals Q2 loss per share $0.35 (NASDAQ:ANTH)
www.reuters.com - August 10 at 10:17 AM
twst.com logoAnthera Pharmaceuticals Inc.: Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results (NASDAQ:ANTH)
www.twst.com - August 10 at 10:17 AM
reuters.com logoBRIEF-Anthera Pharmaceuticals Q2 loss per share $0.35 - Reuters (NASDAQ:ANTH)
www.reuters.com - August 9 at 4:35 PM
nasdaq.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results - Nasdaq (NASDAQ:ANTH)
www.nasdaq.com - August 9 at 4:35 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ANTH)
biz.yahoo.com - August 9 at 4:35 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (NASDAQ:ANTH)
biz.yahoo.com - August 9 at 4:35 PM
twst.com logoAnthera Pharmaceuticals Inc.: Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter ... - The Wall Street Transcript (NASDAQ:ANTH)
www.twst.com - August 9 at 12:16 PM
sg.finance.yahoo.com logoAnthera reports 2Q loss (NASDAQ:ANTH)
sg.finance.yahoo.com - August 9 at 12:16 PM
publicnow.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results (NASDAQ:ANTH)
www.publicnow.com - August 9 at 12:16 PM
tradecalls.org logoAnthera Pharmaceuticals (ANTH) Shares are Up 2.92% - Trade Calls (NASDAQ:ANTH)
www.tradecalls.org - August 8 at 3:33 PM
businesswire.com logoInspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director (NASDAQ:ANTH)
www.businesswire.com - August 4 at 9:16 PM
globenewswire.com logoAnthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod - GlobeNewswire (press release) (NASDAQ:ANTH)
globenewswire.com - August 4 at 12:01 PM
finance.yahoo.com logo4:10 pm Anthera Pharma announces completion of dosing in CHABLIS-SC1 Phase 3 clinical study with Blisibimod (NASDAQ:ANTH)
finance.yahoo.com - August 3 at 9:09 PM
publicnow.com logoAnthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod (NASDAQ:ANTH)
www.publicnow.com - August 3 at 9:09 PM
investingnews.com logoBiotechnology Stocks on Investors’ Radar — Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma (NASDAQ:ANTH)
investingnews.com - August 2 at 3:31 PM
investornewswire.com logoIs $14 Price Target Attainable For Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)? - Investor Newswire (NASDAQ:ANTH)
www.investornewswire.com - July 23 at 3:31 PM
News IconHow Many Anthera Pharmaceuticals Inc (NASDAQ:ANTH)'s Analysts Are Bullish? - Consumer Eagle (NASDAQ:ANTH)
www.consumereagle.com - July 23 at 3:31 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - TGP (NASDAQ:ANTH)
telanaganapress.com - July 22 at 11:43 AM
news.cmlviz.com logoAnthera Pharmaceuticals Inc (NASDAQ:ANTH) Realized Volatility Hits An Elevated Level - CML News (NASDAQ:ANTH)
news.cmlviz.com - July 21 at 9:06 PM
fiscalstandard.com logoAnthera Pharmaceuticals, Inc. (ANTH) Current Analyst Ratings - Fiscal Standard (NASDAQ:ANTH)
www.fiscalstandard.com - July 21 at 3:31 PM
News IconShares Losing Ground in Session: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - TGP (NASDAQ:ANTH)
telanaganapress.com - July 19 at 8:55 PM
News IconAnthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Sellers Increased By 9.1% Their Shorts - Consumer Eagle (NASDAQ:ANTH)
www.consumereagle.com - July 19 at 3:30 PM
News IconEquity Roundup: Stock Performance Focus on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Press Telegraph (NASDAQ:ANTH)
presstelegraph.com - July 19 at 3:30 PM
capitalcube.com logoETF’s with exposure to Anthera Pharmaceuticals, Inc. : July 19, 2016 (NASDAQ:ANTH)
www.capitalcube.com - July 19 at 11:58 AM
News IconInvestor Watch: Volatility Recap on Shares of: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Engelwood Daily (NASDAQ:ANTH)
www.engelwooddaily.com - July 18 at 3:34 PM
News IconShares Moving Down on the Week: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Engelwood Daily (NASDAQ:ANTH)
www.engelwooddaily.com - July 17 at 8:15 AM
News IconShares Experiencing a Downtrend: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - TGP (NASDAQ:ANTH)
telanaganapress.com - July 17 at 8:15 AM
News IconAnthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Short Interest Decreased By 1.01% - Consumer Eagle (NASDAQ:ANTH)
www.consumereagle.com - July 16 at 3:30 PM
News IconGlobal Multiple Myeloma (Kahler Disease) Pipeline 2016 Market Research Review (NASDAQ:ANTH)
www.free-press-release-center.info - July 15 at 2:05 PM
News IconEye on Stock Volatility for: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Engelwood Daily (NASDAQ:ANTH)
www.engelwooddaily.com - July 14 at 3:31 PM
News IconAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:ANTH)
telanaganapress.com - July 14 at 3:31 PM
News IconAnthera Pharmaceuticals Inc (NASDAQ:ANTH) Sentiment Report - Consumer Eagle (NASDAQ:ANTH)
www.consumereagle.com - July 13 at 3:33 PM
News IconAnalyst Target and Average Rating Watch: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Press Telegraph (NASDAQ:ANTH)
presstelegraph.com - July 12 at 7:58 AM

Social

Anthera Pharmaceuticals (NASDAQ:ANTH) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff